Alida Biosciences
Alida Biosciences, founded in 2020 and headquartered in San Diego, is a biotechnology company specializing in epitranscriptomics—the study of RNA modifications that regulate gene expression.
Profile
They develop tools for analyzing RNA modifications to advance disease research and drug development.
Alida Biosciences, founded in 2020 and headquartered in San Diego, is a biotechnology company specializing in epitranscriptomics—the study of RNA modifications that regulate gene expression. The company focuses on developing tools for RNA modification analysis, aiming to advance research in cancer, neurological disorders, and other diseases. AlidaBio's flagship products, EpiPlex and EpiScout, enable multiplexed detection and quantification of RNA modifications from clinically relevant samples, addressing limitations of traditional antibody-based methods.
The company has raised $7.5 million in Series A funding led by Genoa Ventures, with participation from FusionX Ventures and Vertical Venture Partners, and has secured $4 million in SBIR grants from the National Human Genome Research Institute. Recent collaborations include partnerships with STORM Therapeutics for cancer therapy development and DNAnexus for cloud-based data analysis. AlidaBio's technology is positioned to support precision medicine by identifying biomarkers and drug targets through RNA modification profiling.
Products by Alida Biosciences
Who buys this
- Academic and research institutions studying epitranscriptomics
- Biopharmaceutical companies developing RNA-targeted therapies
- Clinical diagnostics firms exploring RNA-based biomarkers
- Contract research organizations (CROs) supporting translational research
Publicly disclosed clients
- STORM Therapeutics
- DNAnexus
- City of Hope National Medical Center
Strengths and what to watch
Strengths
- Proprietary EpiPlex and EpiScout platforms for high-sensitivity RNA modification analysis
- Backing from top-tier investors and non-dilutive SBIR grant funding
- Strategic collaborations with clinical-stage biotechs and cloud genomics platforms
Watch for
- Early-stage company with unproven commercial traction beyond research use
- Dependence on academic and biopharma research budgets vulnerable to funding cycles
- Competition from established NGS and epigenomics tool providers
Recent moves
Key Information
- Founded
- 2020
- Headquarters
- San Diego
Frequently Asked Questions
What does Alida Biosciences do?
Alida Biosciences develops tools for analyzing RNA modifications to advance disease research and drug development. Founded in 2020, the company focuses on epitranscriptomics, studying RNA modifications that regulate gene expression, particularly in cancer and neurological disorders.
What are Alida Biosciences' main products?
Alida Biosciences' flagship products are EpiPlex and EpiScout, which enable multiplexed detection and quantification of RNA modifications from clinically relevant samples. These tools address limitations of traditional antibody-based methods, offering high-sensitivity analysis for research and drug development.
How is Alida Biosciences funded?
Alida Biosciences has raised $7.5 million in Series A funding led by Genoa Ventures, with participation from FusionX Ventures and Vertical Venture Partners. The company has also secured $4 million in SBIR grants from the National Human Genome Research Institute.
What diseases does Alida Biosciences research?
Alida Biosciences focuses on advancing research in cancer, neurological disorders, and other diseases through RNA modification analysis. Their tools help identify biomarkers and drug targets, supporting precision medicine and therapeutic development.
Who are Alida Biosciences' notable clients?
Alida Biosciences collaborates with notable clients like STORM Therapeutics, DNAnexus, and the City of Hope National Medical Center. These partnerships focus on cancer therapy development, cloud-based data analysis, and clinical research in RNA modifications.
What are the applications of Alida Biosciences' technology?
Alida Biosciences' technology is used in academic research, biopharmaceutical drug development, clinical diagnostics, and contract research organizations. Their RNA modification analysis tools support translational research, biomarker discovery, and RNA-targeted therapy development.
Sources
- www.prnewswire.com — Collaboration with STORM Therapeutics
- www.dnanexus.com — Partnership with DNAnexus for cloud-based analysis
- www.biospace.com — Series A funding and product launches
- investor.analog.com — Indirect reference to industry context